<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119285">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01832870</url>
  </required_header>
  <id_info>
    <org_study_id>SIPIPI 2013</org_study_id>
    <nct_id>NCT01832870</nct_id>
  </id_info>
  <brief_title>Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer</brief_title>
  <official_title>Phase 1 Study of Sipuleucel-T and Ipilimumab in Combination for Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prostate Oncology Specialists, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prostate Oncology Specialists, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial designed to quantify the immune response and determine the
      tolerability and side effects of sipuleucel-T when given in combination with ipilimumab for
      patients with advanced prostate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Antigen-specific memory T cell response</measure>
    <time_frame>After last sipuleucel-T and last ipilimumab, and follow-up period, an expected average of 15 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To quantify antigen-specific memory T cell response to sipuleucel-T and ipilimumab in combination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antigen-specific T cell proliferation to PA2024, PAP and PHA</measure>
    <time_frame>After last sipuleucel-T and last ipilimumab, and follow-up period, an expected average of 15 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To quantify Antigen-specific T cell proliferation to PA2024, PAP and PHA when sipuleucel-T and ipilimumab are given in combination.
PA2024 is a recombinant protein
PAP: Prostatic acid phosphatase
PHA: Phytohaemagglutinin, an assay control</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody responses against PA2024 and PAP</measure>
    <time_frame>After last sipuleucel-T and last ipilimumab, and the follow-up period, an expected average of 15 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To quantify antibody responses against PA2024 and PAP.
PA2024 is a recombinant protein
PAP: Prostatic acid phosphatase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostate-Specific Antigen (PSA) doubling time</measure>
    <time_frame>Duration of the study, an expected average of 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To measure changes in PSA doubling time following treatment with sipuleucel-T and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA progression</measure>
    <time_frame>Duration of the study, an expected average of 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To quantify time to PSA progression after treatment with sipuleucel-T and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to salvage therapy</measure>
    <time_frame>Duration of the study, an expected average of 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To quantify time to salvage therapy after treatment with sipuleucel-T and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage PSA decline</measure>
    <time_frame>Duration of the study, an expected average of 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To measure percentage PSA decline following treatment with sipuleucel-T and ipilimumab</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Castrate Resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled will receive the standard 3-dose treatment of sipuleucel-T, followed by treatment(s) of ipilimumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sipuleucel-T</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Provenge</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ipilimumab</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with advanced prostate cancer who are eligible to receive sipuleucel-T in
             accordance with FDA approved labeling of sipuleucel-T

          -  Subjects must understand and sign an informed consent form

        Exclusion Criteria:

          -  Subjects who are not eligible to receive sipuleucel-T
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Scholz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prostate Oncology Specialists, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prostate Oncology Specialists, Inc.</name>
      <address>
        <city>Marina del Rey</city>
        <state>California</state>
        <zip>90292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 24, 2014</lastchanged_date>
  <firstreceived_date>April 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
